Sharon Goldfeld and Yasmin Harman-Smith: Action needed to get children's developmental progress back on track
Australia is fortunate to have one of the world's most comprehensive collections of data on early childhood development in the world. Every three year since 2009, teachers have reported on five key areas of children's development in their first year of school as part of the Australian Early Development Census (AEDC). Last year, with the support of teachers, schools and communities, the AEDC included over 94 per cent of Australian children. This week, the Australian Government released the 2024 results, with the findings suggesting a need for action.
The data tells us that since the last census in 2021, the percentage of children developmentally on track across all five domains of the AEDC – physical health and wellbeing; social competence; emotional maturity; language and cognitive skills (school-based) and communication skills and general knowledge – has declined, at the same time as the number of children experiencing developmental vulnerability has risen.
The findings also highlight that while drivers of this downturn have affected children and families across the socio-economic spectrum, a sizable equity gap in the developmental outcomes of children remains. Children living in the most socio-economically disadvantaged communities experience substantially higher rates of developmental vulnerability compared to their peers growing up in areas with greater access to material resources. These unwelcome trends risk Australia's future prosperity.
To prevent these findings worsening, we need to know what's driving this developmental downturn. Is it related to the COVID-19 lockdowns (these children were babies and toddlers in 2020-22)? A reflection of cost-of-living pressures? Changes to the availability of early childhood intervention services or a lack of access to childcare and universal health services? How social media is affecting children's interactions? Are we effectively responding to children and families' changing needs?
The truth is, we just don't have the answers right now. Hopefully, our research in coming months will help unpack cause and effect, but children's developmental needs must be prioritised. We can't relegate these statistics to a 'watch and wait' approach.
In Prime Minister Anthony Albanese's election night speech, he spoke of building an Australia where 'no one is held back, and no one is left behind' — a future we want for all Australian children.
These results don't need to be the canary in the coalmine. We know from previous AEDC data that we can improve how all children and families are supported in the early years. The crucial questions are what can we do right now to help meet children's early development needs? What plans will address these stark and seemingly immutable inequities? We have enough information to embark on evidence-based policy solutions, with remarkable political will — and capital — at the federal and state level.
We recommend five universal or targeted strategies that should be implemented within current policy commitments which include: Ensuring childcare and preschool is of high-quality, equitable and accessible; delivering on foundational supports through inclusive universal health and education that can identify and respond to child and family needs; stacking high-quality and evidence-based services together in integrated hubs; rapidly implementing the Better and Fairer School Agreement funding to disadvantaged schools with evidence-based strategies to deliver holistic support to all children, especially those with additional needs and embedding the right data systems for local improvement, solutions and accountability to rapidly drive real systems change.
There is a moment when we must stop being a spectator and start acting for change. That time is now. Australia must change the status quo if we are to see improvements reflected in the next AEDC in 2027.
Professor Sharon Goldfeld is Theme Director at Murdoch Children's Research Institute; Associate Professor Yasmin Harman-Smith is Head of the Early Years Systems Evidence Team at The Kids Research Institute Australia
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Sydney Morning Herald
6 hours ago
- Sydney Morning Herald
This breast cancer drug used to cost $3700 a month. From today, it will be much cheaper
Had she not been sponsored, at the time the drugs she was given would have cost her about $4000 a month. 'You think, 'I don't know how we can find this money',' McLardy says. Getting a drug that worked with standard hormone therapy to reduce the chances of cancer returning 'felt like hitting the jackpot,' she says, and helped to reduce the nagging sensation 'that the Grim Reaper had his hand resting on the back of my shoulder'. From July 1, one such drug, ribociclib, sold as Kisqali, will be available on the Pharmaceutical Benefits Scheme (PBS) for women in the initial stages of the most common types of early breast cancer – hormone receptor positive (HR+) or human epidermal growth factor receptor 2 negative (HER2-) – and who are deemed at high risk of recurrence because their cancer involves lymph nodes. The drug is part of a class that targets proteins, known as CDK4/6 inhibitors, involved with division of cancer cells, effectively slowing them down or stopping them from dividing. The global, multi-centre randomised trial, NATALEE, whose findings are published in The New England Journal of Medicine found adding Kisqali to standard endocrine therapy for early breast cancer patients reduced recurrence risk by 28.5 per cent compared with hormone therapy alone. Loading The NATALEE trial involved 5101 patients with HR+/HER2- early breast cancer – which accounts for 70-80 per cent of patients – who were randomly assigned to receive either Kisqali plus hormone therapy or only hormone therapy for three years. Austin Health and Olivia Newton-John Cancer Research Institute oncologist Dr Belinda Yeo said the decision to make Kisqali available to suitable early breast cancer patients would broaden options for treatment intended to cure them. It could be difficult with early breast cancer to discern 'when and to whom' it would return, Yeo said, 'so in the Goldilocks zone of trying to get the right treatment for the right patients, the more options the better'. She described the types of cancer it helps prevent returning as the 'garden varieties', which about 70 per cent of early breast cancer patients have. Around 21,000 people, the vast majority of them women, were diagnosed with breast cancer in 2024. Dr Sally Baron-Hay, an Australian NATALEE phase two study investigator, said it was great to have another treatment option for early breast cancer patients with high-risk cancer involving multiple lymph nodes, but said not all patients at high risk would be eligible. 'My hope is that all my early breast cancer patients at high risk of cancer recurrence, regardless of how many lymph nodes the cancer has involved, will have access to Kisqali in the future,' she said. Kirsten Pilatti, chief executive of the Breast Cancer Network Australia (which accepts no funding from pharmaceutical companies), said the organisation supported the listing of Kisqali on the PBS. Before the listing of Kisqali, women with non-metastatic breast cancer could not access the drug without paying $3700 a month for three years, which some patients do via crowdfunding. Its listing was important because it ensured equity of care, regardless of patients' ability to pay for costly medications privately. 'It is important so we don't have a two-tiered system where only people who can afford it have the benefits,' she said. 'It means more options for precision medicine for oncologists to choose from, for all Australians, regardless of your postcode.' Pilatti, a member of the federal Health Technology Assessment Review Implementation Advisory Group, said access to Kisqali for early breast cancer patients who fit the criteria would help reduce the significant fear of recurrence many experience.
Sydney Morning Herald
9 hours ago
- Sydney Morning Herald
This breast cancer drug used to cost $3700 a month. From today it will be much cheaper
Had she not been sponsored, at the time the drugs she was given would have cost her about $4000 a month. 'You think, 'I don't know how we can find this money',' McLardy says. Getting a drug that worked with standard hormone therapy to reduce the chances of cancer returning 'felt like hitting the jackpot,' she says, and helped to reduce the nagging sensation 'that the Grim Reaper had his hand resting on the back of my shoulder'. From July 1, one such drug, ribociclib, sold as Kisqali, will be available on the Pharmaceutical Benefits Scheme (PBS) for women in the initial stages of the most common types of early breast cancer – hormone receptor positive (HR+) or human epidermal growth factor receptor 2 negative (HER2-) – and who are deemed at high risk of recurrence because their cancer involves lymph nodes. The drug is part of a class that targets proteins, known as CDK4/6 inhibitors, involved with division of cancer cells, effectively slowing them down or stopping them from dividing. The global, multi-centre randomised trial, NATALEE, whose findings are published in the New England Journal of Medicine found adding Kisqali to standard endocrine therapy for early breast cancer patients reduced recurrence risk by 28.5 per cent compared with hormone therapy alone. Loading The NATALEE trial involved 5,101 patients with HR+/HER2- early breast cancer – which accounts for 70-80 per cent of patients – who were randomly assigned to receive either Kisqali plus hormone therapy or only hormone therapy for three years. Austin Health and Olivia Newton John Cancer Research Institute oncologist Dr Belinda Yeo said the decision to make Kisqali available to suitable early breast cancer patients would broaden options for treatment intended to cure them. It could be difficult with early breast cancer to discern 'when and to whom' it would return, Yeo said, 'so in the Goldilocks zone of trying to get the right treatment for the right patients, the more options the better'. She described the types of cancer it helps prevent returning as the 'garden varieties', which about 70 per cent of early breast cancer patients have. Around 21,000 people, the vast majority of them women, were diagnosed with breast cancer in 2024. Dr Sally Baron-Hay, an Australian NATALEE phase two study investigator, said it was great to have another treatment option for early breast cancer patients with high-risk cancer involving multiple lymph nodes, but said not all patients at high risk would be eligible. 'My hope is that all my early breast cancer patients at high risk of cancer recurrence, regardless of how many lymph nodes the cancer has involved, will have access to Kisqali in the future,' she said. Kirsten Pilatti, chief executive of the Breast Cancer Network Australia (which accepts no funding from pharmaceutical companies), said the organisation supported the listing of Kisqali on the PBS. Before the listing of Kisqali, women with non-metastatic breast cancer could not access the drug without paying $3,700 a month for three years, which some patients do via crowdfunding. Its listing was important because it ensured equity of care, regardless of patients' ability to pay for costly medications privately. 'It is important so we don't have a two-tiered system where only people who can afford it have the benefits,' she said. 'It means more options for precision medicine for oncologists to choose from, for all Australians, regardless of your postcode.'
The Age
9 hours ago
- The Age
This breast cancer drug used to cost $3700 a month. From today it will be much cheaper
Had she not been sponsored, at the time the drugs she was given would have cost her about $4000 a month. 'You think, 'I don't know how we can find this money',' McLardy says. Getting a drug that worked with standard hormone therapy to reduce the chances of cancer returning 'felt like hitting the jackpot,' she says, and helped to reduce the nagging sensation 'that the Grim Reaper had his hand resting on the back of my shoulder'. From July 1, one such drug, ribociclib, sold as Kisqali, will be available on the Pharmaceutical Benefits Scheme (PBS) for women in the initial stages of the most common types of early breast cancer – hormone receptor positive (HR+) or human epidermal growth factor receptor 2 negative (HER2-) – and who are deemed at high risk of recurrence because their cancer involves lymph nodes. The drug is part of a class that targets proteins, known as CDK4/6 inhibitors, involved with division of cancer cells, effectively slowing them down or stopping them from dividing. The global, multi-centre randomised trial, NATALEE, whose findings are published in the New England Journal of Medicine found adding Kisqali to standard endocrine therapy for early breast cancer patients reduced recurrence risk by 28.5 per cent compared with hormone therapy alone. Loading The NATALEE trial involved 5,101 patients with HR+/HER2- early breast cancer – which accounts for 70-80 per cent of patients – who were randomly assigned to receive either Kisqali plus hormone therapy or only hormone therapy for three years. Austin Health and Olivia Newton John Cancer Research Institute oncologist Dr Belinda Yeo said the decision to make Kisqali available to suitable early breast cancer patients would broaden options for treatment intended to cure them. It could be difficult with early breast cancer to discern 'when and to whom' it would return, Yeo said, 'so in the Goldilocks zone of trying to get the right treatment for the right patients, the more options the better'. She described the types of cancer it helps prevent returning as the 'garden varieties', which about 70 per cent of early breast cancer patients have. Around 21,000 people, the vast majority of them women, were diagnosed with breast cancer in 2024. Dr Sally Baron-Hay, an Australian NATALEE phase two study investigator, said it was great to have another treatment option for early breast cancer patients with high-risk cancer involving multiple lymph nodes, but said not all patients at high risk would be eligible. 'My hope is that all my early breast cancer patients at high risk of cancer recurrence, regardless of how many lymph nodes the cancer has involved, will have access to Kisqali in the future,' she said. Kirsten Pilatti, chief executive of the Breast Cancer Network Australia (which accepts no funding from pharmaceutical companies), said the organisation supported the listing of Kisqali on the PBS. Before the listing of Kisqali, women with non-metastatic breast cancer could not access the drug without paying $3,700 a month for three years, which some patients do via crowdfunding. Its listing was important because it ensured equity of care, regardless of patients' ability to pay for costly medications privately. 'It is important so we don't have a two-tiered system where only people who can afford it have the benefits,' she said. 'It means more options for precision medicine for oncologists to choose from, for all Australians, regardless of your postcode.'
